| 1 |
朱家恺. 外科学辞典[M]. 北京: 北京科学技术出版社, 2003.
|
| 2 |
KANEKO K, ITO M, FUMOTO T, et al. Physiological function of the angiotensin AT1a receptor in bone remodeling[J]. J Bone Miner Res, 2011, 26(12): 2959-2966.
|
| 3 |
SPERETTA G F, RUCHAYA P J, DELBIN M A, et al. Importance of AT1 and AT2 receptors in the nucleus of the solitary tract in cardiovascular responses induced by a high-fat diet[J]. Hypertens Res, 2019, 42(4): 439-449.
|
| 4 |
黎秀芝, 尹新华. ACE2/Ang(1-7)/Mas轴在心血管疾病中的研究进展[J]. 医学综述, 2020, 26(20): 3969-3975.
|
| 5 |
BAYOMY O, ZAHEER S, WILLIAMS J S, et al. Disentangling the relationships between the renin-angiotensin-aldosterone system, calcium physiology, and risk for kidney stones[J]. J Clin Endocrinol Metab, 2020, 105(6): 1937-1946.
|
| 6 |
HATTON R, STIMPEL M, CHAMBERS T J. Angiotensin Ⅱ is generated from angiotensin Ⅰ by bone cells and stimulates osteoclastic bone resorption in vitro[J]. J Endocrinol, 1997, 152(1): 5-10.
|
| 7 |
樊长萍, 侯建明. 原发性醛固酮增多症与骨质疏松症的相关性[J]. 中华骨质疏松和骨矿盐疾病杂志, 2016, 9(2): 199-204.
|
| 8 |
SALAM S, GALLAGHER O, HUGHES D, et al. The role of static bone histomorphometry in diagnosing renal osteodystrophy[J]. Bone, 2021, 142: 115689.
|
| 9 |
FERREIRA A C, COHEN-SOLAL M, D’HAESE P C, et al. The Role of Bone Biopsy in the Management of CKD-MBD[J]. Calcif Tissue Int, 2021,108(4):528-538.
|
| 10 |
JØRGENSEN H S, BEHETS G, VIAENE L, et al. Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels[J]. Bone, 2021, 152: 116066.
|
| 11 |
李红芬, 林珊, 贾俊亚, 等. 长期低剂量1α,25-二羟基维生素D3对尿毒症大鼠肾脏水通道蛋白2表达的影响[J]. 中华肾脏病杂志, 2013, 29(2): 124-128.
|
| 12 |
祝再然, 林 珊, 贾俊亚, 等. 长期接受不同饮食磷水平的慢性肾衰竭大骨组织形态学特征改变[J]. 北京医学, 2011, 33(2): 167-169.
|
| 13 |
PAZIANAS M, MILLER P D. Osteoporosis and chronic kidney disease-mineral and bone disorder(CKD-MBD): back to basics[J]. Am J Kidney Dis, 2021, 78(4): 582-589.
|
| 14 |
TSUJI K, KITAMURA M, CHIBA K, et al. Comparison of bone microstructures via high-resolution peripheral quantitative computed tomography in patients with different stages of chronic kidney disease before and after starting hemodialysis[J]. Ren Fail, 2022, 44(1): 381-391.
|
| 15 |
NEYRA J A, HU M C, MOE O W. Klotho in clinical nephrology: diagnostic and therapeutic implications[J]. Clin J Am Soc Nephrol, 2020, 16(1): 162-176.
|
| 16 |
SAAR-KOVROV V, DONNERS M M P C, VAN DER VORST E P C. Shedding of klotho: functional implications in chronic kidney disease and associated vascular disease[J]. Front Cardiovasc Med, 2021, 7: 617842.
|
| 17 |
程 虹. 中晚期慢性肾脏病患者血管钙化管理[J]. 中国实用内科杂志, 2023, 43(3): 218-224.
|
| 18 |
汤 曦, 石运莹, 王俭勤, 等. 中国成人慢性肾脏病及其并发症早期筛查临床路径专家建议(2023版)[J]. 中国实用内科杂志, 2023, 43(3): 198-205.
|
| 19 |
KONO K, FUJII H, WATANABE K. Relationship between parathyroid hormone and renin-angiotensin-aldosterone system in hemodialysis patients with secondary hyperparathyroidism[J]. J Bone Miner Metab, 2021, 39(2): 230-236.
|
| 20 |
WANG Y L, MA W X, PU J H, et al. Interrelationships between sarcopenia, bone turnover markers and low bone mineral density in patients on hemodialysis[J]. Ren Fail, 2023, 45(1): 2200846.
|
| 21 |
PARK S Y, AHN S H, YOO J I, et al. Position statement on the use of bone turnover markers for osteoporosis treatment[J]. J Bone Metab, 2019, 26(4): 213-224.
|
| 22 |
WU J, WANG M, GUO M, et al. Angiotensin receptor blocker is associated with a lower fracture risk: an updated systematic review and meta-analysis[J]. Int J Clin Pract, 2022, 2022: 7581110.
|
| 23 |
QUEIROZ-JUNIOR C M, SANTOS A C P M, GALVÃO I, et al. The angiotensin converting enzyme 2/angiotensin-(1-7)/Mas Receptor axis as a key player in alveolar bone remodeling[J]. Bone, 2019, 128: 115041.
|
| 24 |
章海涛. 新型盐皮质激素受体拮抗剂的临床应用[J]. 肾脏病与透析肾移植杂志, 2021,30(5): 449-450.
|
| 25 |
TIWARI P, TIWARI V, GUPTA S, et al.Activation of angiotensin-converting enzyme 2 protects against lipopolysaccharide-induced glial activation by modulating angiotensin-converting enzyme 2/angiotensin(1-7)/mas receptor axis[J]. Mol Neurobiol,2023, 60(1): 203-227.
|